All Stories

  1. Renin–angiotensin system inhibitors (RASi) are not nephrotoxic – they protect the kidneys and the heart
  2. Changes in renal perfusion with brainstem death – revisiting the hypothesis of sympathetically mediated organ hypoperfusion
  3. Top Ten Tips to Manage Patients after Acute Kidney Injury (AKI)
  4. The impact of social determinants of health on acute kidney injury
  5. Hemoadsorption Combined with Hemodialysis (HAHD): a Consensus Statement from an International Expert Panel
  6. Kidney health during critical illness or upon major surgery
  7. European Society of Intensive Care Medicine Clinical Practice Guideline on fluid therapy in adult critically ill patients: A path toward improved patient management
  8. The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup
  9. The global epidemiology of acute kidney injury: challenges and opportunities
  10. Update on acute kidney injury: some progresses and a long way to go
  11. Diagnosis, diagnostic approach and challenges in pregnancy-associated AKI – The ADQI 32 consensus meeting
  12. Selected Serious Adverse Events in a Cohort of Adult ICU Patients: Protocol for a Sub‐Study of the PATIENCE Cohort
  13. European Society of Intensive Care Medicine Clinical Practice Guideline on fluid therapy in adult critically ill patients: Part 3—fluid removal at de-escalation phase
  14. State of the art: Renal recovery after AKI - from basic science to clinical practice
  15. Renal tubular epithelial cells: A revived kidney biomarker?
  16. Correction: Understanding and mitigating medication errors associated with patient harm in adult intensive care units: a scoping review
  17. Sepsis criteria and kidney function: eliminating sex, age and economic status biases
  18. Understanding and mitigating medication errors associated with patient harm in adult intensive care units: a scoping review
  19. Persistent severe AKI is bad—where to go now?
  20. Systematic Review and Meta-Analysis of Machine Learning Models for Acute Kidney Injury Risk Classification
  21. The effects of urine alkalinization on kidney function in critically ill patients with COVID-19: a proof-of-concept randomized clinical trial
  22. Kidney expert consultation and the outcomes of in hospital acute kidney injury
  23. Expanding the role of PoCUS in tailoring diuretic strategies for congestion management in critical care: authors’ reply
  24. The impact of Intensive Care Strain on Patients’ Outcomes during COVID-19 - a UNITE COVID study
  25. Hemoadsorption in septic shock – PRO
  26. NephroCheck AKI risk scores (TIMP-2 and IGFBP7) in pregnancy
  27. The heart–kidney axis in cirrhosis: rethinking hepatorenal and cardiorenal syndromes—authors’ reply
  28. DEFENDER trial: dapagliflozin for critically ill patients with acute organ dysfunction—implications for clinicians
  29. Ethical considerations in research involving ICU patients who lack capacity: navigating the updated Helsinki Declaration
  30. Can we use artificial intelligence to better treat acute kidney injury?
  31. Perioperative fluid management: evidence-based consensus recommendations from the international multidisciplinary PeriOperative Quality Initiative
  32. Terlipressin use in hepatorenal syndrome—acute kidney injury in cirrhosis. Author’s reply
  33. Environmental sustainability in intensive care: the path forward. An ESICM Green Paper
  34. Biomarkers in acute kidney injury
  35. Does amino acid infusion improve kidney outcomes in patients at high risk for postsurgical AKI?
  36. Terlipressin use in HRS–AKI and respiratory failure. Author's reply
  37. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting
  38. Preferences for albumin use in adult intensive care unit patients with shock: An international survey
  39. The REPERFUSE study protocol: The effects of vasopressor therapy on renal perfusion in patients with septic shock—A mechanistically focused randomised control trial
  40. Adjudication of a primary trial outcome: Results of a calibration exercise and protocol for a large international trial
  41. Using diuretic therapy in the critically ill patient
  42. Hepatorenal syndrome in the intensive care unit
  43. The environmental impact of laboratory measurements in high-resource ICUs
  44. Hemoadsorption
  45. Acute kidney injury in patients with burns
  46. Designing acute kidney injury clinical trials
  47. Micronutrient use in critical care: Survey of clinical practice
  48. Raised FGF23 Correlates to Increased Mortality in Critical Illness, Independent of Vitamin D
  49. Diuretics and ultrafiltration in heart failure
  50. Acute kidney injury
  51. Paths to organ damage and risk factors in AKI
  52. Improving risk prediction model quality in the critically ill: data linkage study
  53. Management of oliguria
  54. Indications for and Timing of Initiation of KRT
  55. Onco-nephrology: what the intensivist needs to know
  56. On myths about albumin and misconceptions that cause confusion: authors’ reply to “What’s wrong with the ten myths about albumin: three layers for an indisputable dispute”
  57. Ten myths about Albumin: don’t forget the endothelium. Author’s reply
  58. Erratum: Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study
  59. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study
  60. Extracorporeal Blood Purification Is Appropriate in Critically Ill Patients with COVID-19 and Multiorgan Failure: COMMENTARY
  61. Correction: Ten myths about albumin
  62. Ten myths about albumin
  63. Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study
  64. Dapagliflozin in patients with COVID-19: mind the kidneys
  65. Angiotensin II infusion in COVID‐19: An international, multicenter, registry‐based study
  66. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  67. Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup
  68. The AKI care bundle: all bundle components are created equal—are they?
  69. Current practice and evolving concepts in septic shock resuscitation
  70. Renal replacement therapy in extra-corporeal membrane oxygenation patients: A survey of practices and new insights for future studies
  71. Do ventilatory parameters influence outcome in patients with severe acute respiratory infection? Secondary analysis of an international, multicentre14-day inception cohort study
  72. Cardiac Surgery Associated AKI Prevention Strategies and Medical Treatment for CSA-AKI
  73. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
  74. Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021
  75. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
  76. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
  77. Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study
  78. Vascular access support teams: A multi-disciplinary response to optimise patient care during the COVID-19 pandemic
  79. Acute kidney injury in patients treated with immune checkpoint inhibitors
  80. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning
  81. Definitions of acute renal dysfunction: an evolving clinical and biomarker paradigm
  82. Discharge Documentation and Follow-Up of Critically Ill Patients With Acute Kidney Injury Treated With Kidney Replacement Therapy: A Retrospective Cohort Study
  83. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
  84. Acute kidney injury in ECMO patients
  85. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
  86. Biomarker-Based Management of AKI: Fact or Fantasy?
  87. Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study
  88. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
  89. Acute kidney injury in the critically ill: an updated review on pathophysiology and management
  90. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
  91. Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study
  92. Nutrients and micronutrients at risk during renal replacement therapy: a scoping review
  93. Perioperative use of serum creatinine and postoperative acute kidney injury: a single-centre, observational retrospective study to explore physicians’ perception and practice
  94. Long-term kidney function of patients discharged from hospital after an intensive care admission: observational cohort study
  95. Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative
  96. Prevention of Cardiac Surgery–Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial
  97. Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial
  98. Limiting Acute Kidney Injury Progression In Sepsis: Study Protocol and Trial Simulation*
  99. Nutritional assessment and support during continuous renal replacement therapy
  100. FGF23 ameliorates ischemia-reperfusion induced acute kidney injury via modulation of endothelial progenitor cells: targeting SDF-1/CXCR4 signaling
  101. Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup
  102. Wait and see for acute dialysis: but for how long?
  103. Predicting AKI: do we have the necessary tools?
  104. Early sedation with dexmedetomidine in ventilated critically ill patients and heterogeneity of treatment effect in the SPICE III randomised controlled trial
  105. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
  106. Reduced exposure to vasopressors through permissive hypotension to reduce mortality in critically ill people aged 65 and over: the 65 RCT
  107. Association of plasma and urine NGAL with acute kidney injury after elective colorectal surgery: A cohort study
  108. Preventing infectious diseases in Intensive Care Unit by medical devices remote control: Lessons from COVID-19
  109. Surviving Sepsis Campaign: Guidelines on caring for critically ill COVID-19 patients
  110. Clearance of inflammatory cytokines in patients with septic acute kidney injury during renal replacement therapy using the EMiC2 filter (Clic-AKI study)
  111. Clearance of inflammatory cytokines in Patients with Septic Acute Kidney Injury During Renal Replacement Therapy Using the EMiC2 Filter (Clic-AKI study)
  112. Use of Biomarkers to Identify Acute Kidney Injury to Help Detect Sepsis in Patients With Infection
  113. In-House Production of Dialysis Solutions to Overcome Challenges During the Coronavirus Disease 2019 Pandemic
  114. What every Intensivist should know about COVID-19 associated acute kidney injury
  115. Net ultrafiltration prescription survey in Europe
  116. COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review
  117. Preferences for the measurement and supplementation of magnesium, phosphate and zinc in ICUs: The international WhyTrace survey
  118. Clearance of Inflammatory Cytokines in Patients with Septic Acute Kidney Injury During Renal Replacement Therapy Using the EMiC2 Filter (Clic-AKI Study)
  119. Neuromuscular blockade in patients with ARDS: a rapid practice guideline
  120. Clearance of micronutrients during continuous renal replacement therapy
  121. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
  122. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference
  123. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup
  124. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
  125. Can Ventilatory Strategies in COVID-19 Have an Impact on Outcomes?<b> </b>
  126. Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial
  127. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury
  128. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock
  129. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study
  130. Parenteral thiamine for prevention and treatment of delirium in critically ill adults: a systematic review protocol
  131. Fluid removal associates with better outcomes in critically ill patients receiving continuous renal replacement therapy: a cohort study
  132. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
  133. Roles of angiotensin II as vasopressor in vasodilatory shock
  134. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation
  135. Acute kidney injury in critically ill cancer patients is associated with mortality: A retrospective analysis
  136. Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study
  137. Fluid management knowledge in hospital physicians: ‘Greenshoots’ of improvement but still a cause for concern
  138. Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B
  139. Renal replacement anticoagulant management: Protocol and analysis plan for an observational comparative effectiveness study of linked data sources
  140. A Multinational Observational Study Exploring Adherence With the Kidney Disease
  141. Pro: We Should Stop ACE Inhibitors Early Before Cardiac Surgery to Prevent Postoperative AKI
  142. Biomarker-guided implementation of the KDIGO guidelines to reduce the occurrence of acute kidney injury in patients after cardiac surgery (PrevAKI-multicentre): protocol for a multicentre, observational study followed by randomised controlled feasibili...
  143. The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study
  144. Protocol and statistical analysis plan for the REstricted fluid therapy VERsus Standard trEatment in Acute Kidney Injury—REVERSE‐AKI randomized controlled pilot trial
  145. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study
  146. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
  147. Acute kidney injury as a risk factor of hyperactive delirium: A case control study
  148. Net Ultrafiltration Prescription and Practice Among Critically Ill Patients Receiving Renal Replacement Therapy
  149. Creatinine: From physiology to clinical application
  150. Micronutrients in critically ill patients with severe acute kidney injury – a prospective study
  151. A narrative review of the impact of surgery and anaesthesia on acute kidney injury
  152. Long‐term patient‐important outcomes after septic shock: A protocol for 1‐year follow‐up of the CLASSIC trial
  153. Lung–kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup
  154. Cumulative fluid accumulation is associated with the development of acute kidney injury and non-recovery of renal function: a retrospective analysis
  155. Report of the first AKI Round Table meeting: an initiative of the ESICM AKI Section
  156. How much centralization of critical care services in the era of telemedicine?
  157. Optimizing renal replacement therapy for patients who need extracorporeal membrane oxygenation: cross-talk between two organ support machines
  158. Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study)
  159. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project
  160. Acute Kidney Injury and Septic Shock—Defined by Updated Sepsis-3 Criteria in Critically Ill Patients
  161. Fluid Management in Acute Kidney Injury
  162. Vasopressor Therapy and Blood Pressure Management in the Setting of Acute Kidney Injury
  163. Less is more: ten reasons for considering to discontinue unproven interventions
  164. Renal replacement therapy for acute kidney injury in intensive care
  165. Conservative vs liberal fluid therapy in septic shock (CLASSIC) trial—Protocol and statistical analysis plan
  166. Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin–Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study
  167. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
  168. Changes in critically ill cancer patients’ short-term outcome over the last decades: results of systematic review with meta-analysis on individual data
  169. Quality Improvement Goals for Acute Kidney Injury
  170. Renal function after out-of-hospital cardiac arrest; the influence of temperature management and coronary angiography, a post hoc study of the target temperature management trial
  171. How to feed a patient with acute kidney injury
  172. Broad spectrum vasopressors: a new approach to the initial management of septic shock?
  173. Cumulative Prognostic Score Predicting Mortality in Patients Older Than 80 Years Admitted to the ICU
  174. Statement paper on diversity for the European Society of Intensive Care Medicine (ESICM)
  175. Distance between the tips of central venous catheters does not depend on same or opposite site access
  176. Diagnosis of death using neurological criteria in adult patients on extracorporeal membrane oxygenation: Development of UK guidance
  177. Challenges in the management of septic shock: a narrative review
  178. 10 myths about frusemide
  179. Ten tips to manage renal transplant recipients
  180. Serial Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness
  181. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: Study Protocol for a Multi-National, Multi-Center, Randomized Controlled Trial
  182. Continuous renal replacement therapy during extracorporeal membrane oxygenation
  183. Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data
  184. Risk prediction for acute kidney injury in acute medical admissions in the UK
  185. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury
  186. Angiotensin in ECMO patients with refractory shock
  187. Unrecognised myocardial infarction and its relationship to outcome in critically ill patients with cardiovascular disease
  188. Correction to: Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit
  189. suPAR as a marker of infection in acute kidney injury – a prospective observational study
  190. MAP of 65: target of the past?
  191. Cardiac and Vascular Surgery–Associated Acute Kidney Injury: The 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group
  192. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial
  193. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
  194. Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit
  195. Exploring the impact of using measured or estimated values for height and weight on the relationship between BMI and acute hospital mortality
  196. Pragmatic studies for acute kidney injury: Consensus report of the Acute Disease Quality Initiative (ADQI) 19 Workgroup
  197. Angiotensin in Critical Care
  198. Erratum to “Intraoperative permissive oliguria – how much is too much?” [Br J Anaesth 119 (2017) 1075–1077]
  199. Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults
  200. Techniques and Modalities of Continuous Renal Replacement Therapy
  201. The Burden of Acute Kidney Injury and Related Financial Issues
  202. Drug management in acute kidney disease - Report of the Acute Disease Quality Initiative XVI meeting
  203. Intraoperative permissive oliguria – how much is too much?
  204. The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature
  205. Correction to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study
  206. The effect of regional citrate anti-coagulation on the coagulation system in critically ill patients receiving continuous renal replacement therapy for acute kidney injury - an observational cohort study
  207. Characteristics and Outcome of Cancer Patients Admitted to the ICU in England, Wales, and Northern Ireland and National Trends Between 1997 and 2013*
  208. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years)
  209. Pathophysiology of AKI
  210. Early troponin I in critical illness and its association with hospital mortality: a cohort study
  211. Angiotensin II for the Treatment of Vasodilatory Shock
  212. Elevated preoperative heart rate is associated with cardiopulmonary and autonomic impairment in high-risk surgical patients
  213. Renal Support for Acute Kidney Injury in the Developing World
  214. Vitamin D levels in critically ill patients with acute kidney injury: a protocol for a prospective cohort study (VID-AKI)
  215. Cardiac Troponin Release is Associated with Biomarkers of Inflammation and Ventricular Dilatation During Critical Illness
  216. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017
  217. Low mean perfusion pressure is a risk factor for progression of acute kidney injury in critically ill patients – A retrospective analysis
  218. Renal recovery after acute kidney injury
  219. Diagnostic work-up and specific causes of acute kidney injury
  220. Have renal biomarkers failed in acute kidney injury? Yes
  221. Cardiac biomarkers are associated with maximum stage of acute kidney injury in critically ill patients: a prospective analysis
  222. The AKI glossary
  223. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury
  224. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup
  225. Predictions are difficult…especially about AKI
  226. The intensive care medicine agenda on acute kidney injury
  227. Lymphocyte Function in Human Acute Kidney Injury
  228. In critically ill patients with acute kidney injury stage 2, early initiation of renal replacement therapy is associated with reduced 90-day mortality compared to delayed initiation
  229. Intravascular versus surface cooling for targeted temperature management after out-of-hospital cardiac arrest – an analysis of the TTM trial data
  230. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications
  231. Nomenclature for renal replacement therapy in acute kidney injury: basic principles
  232. Short-term and medium-term survival of critically ill patients with solid tumours admitted to the intensive care unit: a retrospective analysis
  233. Acute kidney injury 2016: diagnosis and diagnostic workup
  234. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock
  235. The two sides of creatinine: both as bad as each other?
  236. Goal-directed therapy and acute kidney injury: as good as it gets?
  237. The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients
  238. Fatal cardiovascular instability secondary to hypercalcaemia and intracellular calcium deposition complicating T-cell leukaemia-lymphoma
  239. Diuretics in critical illness
  240. Anaemia is not a risk factor for progression of acute kidney injury: a retrospective analysis
  241. Incidence of tuberculosis is high in chronic kidney disease patients in South East England and drug resistance common
  242. Patient Selection and Timing of Continuous Renal Replacement Therapy
  243. Timing of Renal Replacement Therapy in Acute Kidney Injury
  244. Fluid overload and acute kidney injury: cause or consequence?
  245. Citrate anticoagulation for CRRT: don’t always trust the postfilter iCa results!
  246. Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
  247. Ionized calcium measurements during regional citrate anticoagulation in CRRT: we need better blood gas analyzers
  248. Increased Fluid Administration After Early Acute Kidney Injury is Associated with Less Renal Recovery
  249. Revised algorithm for heparin anticoagulation during continuous renal replacement therapy
  250. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients ...
  251. Fluid Composition and Clinical Effects
  252. Recognition and management of acute kidney injury in hospitalised patients can be partially improved with the use of a care bundle
  253. Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
  254. AKI and haemodynamics
  255. Mood and illness experiences of adults with cystinosis
  256. Failure of Anticoagulant Thromboprophylaxis
  257. Timing of Renal Replacement Therapy
  258. Acute Kidney Injury Biomarkers
  259. Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes
  260. Dose of Renal Replacement Therapy in AKI
  261. The definition of acute kidney injury and its use in practice
  262. Diagnosis of acute kidney injury
  263. Biomarkers for AKI improve clinical practice: no
  264. Novel risk factors for acute kidney injury
  265. Indications and management of mechanical fluid removal in critical illness
  266. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study
  267. Nonleg Venous Thrombosis in Critically Ill Adults
  268. Prevention, detection and management of acute kidney injury: concise guideline
  269. DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current  -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
  270. Correction of Hyper- and Hyponatraemia during Continuous Renal Replacement Therapy
  271. Echocardiography Predicts Major Adverse Cardiovascular Events after Renal Transplantation
  272. Measuring biomarkers of acute kidney injury during renal replacement therapy: wisdom or folly?
  273. A prospective study of the impact of serial troponin measurements on the diagnosis of myocardial infarction and hospital and six-month mortality in patients admitted to ICU with non-cardiac diagnoses
  274. Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
  275. Genome-Wide Sequencing of Cellular microRNAs Identifies a Combinatorial Expression Signature Diagnostic of Sepsis
  276. Restrictive Versus Liberal Transfusion Strategies for Older Mechanically Ventilated Critically Ill Patients
  277. Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis
  278. Heparin-Induced Thrombocytopenia in Medical Surgical Critical Illness
  279. Acute kidney injury: summary of NICE guidance
  280. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis
  281. Acute kidney injury after cardiac surgery according to Risk/Injury/Failure/Loss/End-stage, Acute Kidney Injury Network, and Kidney Disease: Improving Global Outcomes classifications
  282. Predicting the development of acute kidney injury in liver cirrhosis - an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers
  283. RCPE UK Consensus Conference Statement: Management of acute kidney injury: the role
  284. Rates and determinants of informed consent: A case study of an international thromboprophylaxis trial
  285. Outcomes of Chronic Hemodialysis Patients in the Intensive Care Unit
  286. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
  287. Improved Outcome of Severe Acute Pancreatitis in the Intensive Care Unit
  288. Retrospective analysis of outcome of women with breast or gynaecological cancer in the intensive care unit
  289. Beyond the Randomized Clinical Trial: Citrate for Continuous Renal Replacement Therapy in Clinical Practice
  290. Maintaining Normal Levels of Ionized Calcium during Citrate-Based Renal Replacement Therapy Is Associated with Stable Parathyroid Hormone Levels
  291. Letters to the editor
  292. Intravenous fluid use in the acutely unwell adult medical inpatient: improving practice through a clinical audit process
  293. Faculty of 1000 evaluation for Clinical factors associated with initiation of renal replacement therapy in critically ill patients with acute kidney injury-A prospective multicenter observational study.
  294. Successful management of severe hyponatraemia during continuous renal replacement therapy
  295. Renal replacement therapy in critically ill patients with acute kidney injury--when to start
  296. Care of the Critically Ill Emergency Department Patient with Acute Kidney Injury
  297. Clinical review: Biomarkers of acute kidney injury: where are we now?
  298. Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice
  299. Impact of different types of organ failure on outcome in intensive care unit patients with acute kidney injury
  300. Choice of Renal Replacement Therapy and Role of Haemodialysis in the Intensive Care Unit
  301. Role of Implantable Cardioverter Defibrillators for Dialysis Patients
  302. Challenges of defining acute kidney injury
  303. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease
  304. ICU and 6-month outcome of oncology patients in the intensive care unit
  305. Intensity of Continuous Renal-Replacement Therapy
  306. Management of sodium disorders during continuous haemofiltration
  307. Heparin algorithm for anticoagulation during continuous renal replacement therapy
  308. Effect of "collaborative requesting" on consent rate for organ donation: randomised controlled trial (ACRE trial)
  309. Response to ‘Could N-terminal pro-BNP be a useful marker for prediction of cardiac arrests in hemodialysis patients?’
  310. Correlation between parameters at initiation of renal replacement therapy and outcome in patients with acute kidney injury
  311. Cardiac arrests in hemodialysis patients: An ongoing challenge
  312. Acute Renal Failure in the Surgical Patient
  313. Renal failure in the intensive care unit: acute kidney injury compared to end-stage renal failure
  314. Correlation between the AKI classification and outcome
  315. Acute kidney injury on admission to the intensive care unit: where to go from here?
  316. The RIFLE criteria: Are the foundations robust?
  317. Frusemide Administration in Critically Ill Patients by Continuous Compared to Bolus Therapy
  318. Acute kidney injury in the intensive care unit according to RIFLE*
  319. Octreotide for relapsing sulfonylurea-induced hypoglycemia in a dialysis patient
  320. ACUTE RENAL FAILURE IN ICU - EVALUATION OF THE RIFLE CLASSIFICATION.
  321. Differential inducible nitric oxide synthase activity in circulating neutrophils vs. mononuclears of septic shock patients
  322. Prognosis of acute renal failure: an evaluation of proposed consensus criteria
  323. Pre-existing renal failure doubles 30-day mortality after heart transplantation
  324. Metabolic alkalosis in patients with renal failure
  325. Haemodialysis patients' views on their resuscitation status
  326. A 67‐year‐old kidney transplant patient with headache of uncertain origin
  327. Prophylaxis of cytomegalovirus infection in renal transplantation
  328. Coma mimicking brain death following baclofen overdose
  329. Acute renal failure following cardiopulmonary bypass: a changing picture
  330. Sedation in the Intensive Care Unit
  331. Lipid Profiles in Patients with Atherosclerotic Renal Artery Stenosis
  332. Effect of continuous haemofiltration on essential micronutrient levels
  333. Faculty of 1000 evaluation for Preoperative Statin Use and Postoperative Acute Kidney Injury.
  334. Faculty of 1000 evaluation for The fallacy of the BUN:creatinine ratio in critically ill patients.
  335. Faculty of 1000 evaluation for Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials.
  336. Faculty of 1000 evaluation for Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy.
  337. Faculty of 1000 evaluation for Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial.
  338. Faculty of 1000 evaluation for Sodium bicarbonate infusion to reduce cardiac surgery-associated acute kidney injury: a phase II multicenter double-blind randomized controlled trial.
  339. Faculty of 1000 evaluation for Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial.
  340. Faculty of 1000 evaluation for Are Autopsy Findings Still Relevant to the Management of Critically Ill Patients in the Modern Era?
  341. Faculty of 1000 evaluation for Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial.